000119951 001__ 119951
000119951 005__ 20240319081019.0
000119951 0247_ $$2doi$$a10.3390/pharmaceutics14102064
000119951 0248_ $$2sideral$$a130733
000119951 037__ $$aART-2022-130733
000119951 041__ $$aeng
000119951 100__ $$aMármol, Inés
000119951 245__ $$aBiological Activity of NHC-Gold-Alkynyl Complexes Derived from 3-Hydroxyflavones
000119951 260__ $$c2022
000119951 5060_ $$aAccess copy available to the general public$$fUnrestricted
000119951 5203_ $$aIn this paper we describe the synthesis of new N-heterocyclic carbene (NHC) gold(I) derivatives with flavone-derived ligands with a propargyl ether group. The compounds were screened for their antimicrobial and anticancer activities, showing greater activity against bacteria than against colon cancer cells (Caco-2). Complexes [Au(L2b)(IMe)] (1b) and [Au(L2b)(IPr)] (2b) were found to be active against both Gram-positive and Gram-negative strains. The mechanism of action of 1b was evaluated by measurement of thioredoxin reductase (TrxR) and dihydrofolate reductase (DHFR) activity, besides scanning electron microscopy (SEM). Inhibition of the enzyme thioredoxin reductase is not observed in either Escherichia Coli or Caco-2 cells; however, DHFR activity is compromised after incubation of E. coli cells with complex 1b. Moreover, loss of structural integrity and change in bacterial shape is observed in the images obtained from scanning electron microscopy (SEM) after treatment E. coli cells with complex 1b.
000119951 536__ $$9info:eu-repo/grantAgreement/ES/DGA/E07-20R$$9info:eu-repo/grantAgreement/ES/AEI/PID2019-104379RB-C21$$9info:eu-repo/grantAgreement/ES/CIBERObn/CB06-03-1012$$9info:eu-repo/grantAgreement/ES/DGA/B16-R17$$9info:eu-repo/grantAgreement/ES/MICINN-AEI/RED2018-102471-T$$9info:eu-repo/grantAgreement/ES/MICINN-AEI/SAF2016-75441-R$$9info:eu-repo/grantAgreement/EUR/SUDOE/INTERREG/Redvalue-SOE1-PI-E0123
000119951 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000119951 590__ $$a5.4$$b2022
000119951 592__ $$a0.795$$b2022
000119951 591__ $$aPHARMACOLOGY & PHARMACY$$b50 / 278 = 0.18$$c2022$$dQ1$$eT1
000119951 593__ $$aPharmaceutical Science$$c2022$$dQ1
000119951 594__ $$a6.9$$b2022
000119951 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000119951 700__ $$aQuero, Javier
000119951 700__ $$aAzcárate, Paula
000119951 700__ $$0(orcid)0000-0002-3830-7847$$aAtrián-Blasco, Elena
000119951 700__ $$aRamos, Carla
000119951 700__ $$aSantos, Joana
000119951 700__ $$aGimeno, María Concepción
000119951 700__ $$0(orcid)0000-0002-3595-7668$$aRodríguez-Yoldi, María Jesús$$uUniversidad de Zaragoza
000119951 700__ $$0(orcid)0000-0003-2457-3674$$aCerrada, Elena$$uUniversidad de Zaragoza
000119951 7102_ $$12010$$2760$$aUniversidad de Zaragoza$$bDpto. Química Inorgánica$$cÁrea Química Inorgánica
000119951 7102_ $$11012$$2410$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Fisiología
000119951 773__ $$g14, 10 (2022), 2064 [15 pp.]$$pPharmaceutics$$tPharmaceutics$$x1999-4923
000119951 8564_ $$s14033000$$uhttps://zaguan.unizar.es/record/119951/files/texto_completo.pdf$$yVersión publicada
000119951 8564_ $$s2773570$$uhttps://zaguan.unizar.es/record/119951/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000119951 909CO $$ooai:zaguan.unizar.es:119951$$particulos$$pdriver
000119951 951__ $$a2024-03-18-15:59:07
000119951 980__ $$aARTICLE